NCT04560608

Brief Summary

Statement :

  • The emerging Coronavirus 2019 (COVID-19) disease, linked to the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pathogen, has been spreading worldwide since December 2019, affecting millions of people and causing hundreds of thousands of deaths, particularly among the elderly.
  • The first epidemiological evidence available reveals a different expression of the disease in the elderly, associated with a high risk of delayed diagnosis and implementation of protective measures and a particularly high morbidity and mortality, especially among the frailest.
  • To date, there is no effective model for predicting the severity of COVID-19 in an individual. The investigators hypothesize that there are specificities of COVID-19 in the elderly, both etiological, diagnostic and prognostic, all of which are not yet known and understood.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
700

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 15, 2020

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 8, 2020

Completed
15 days until next milestone

First Posted

Study publicly available on registry

September 23, 2020

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

December 20, 2021

Status Verified

December 1, 2021

Enrollment Period

2.8 years

First QC Date

September 8, 2020

Last Update Submit

December 3, 2021

Conditions

Keywords

elderlycoronavirus disease

Outcome Measures

Primary Outcomes (14)

  • Medical history and co-morbidities

    listing of medical history and co-morbidities data provided by the physician and the family during hospitalization

    baseline

  • The physical examination data, and reports of relevant investigations data provided by the physician and the family during hospitalization

    The demographic characteristics are age, sex, marital status, place of life, career, presence of un/formal assistance, …

    baseline

  • Electrocardiography QT Interval

    all electrocardiograms performed during hospitalization

    baseline

  • Number of different therapeutic classes

    Number of different therapeutic classes taken per day.

    baseline

  • Comprehensive Geriatric Assessment (CGA)

    Comprehensive geriatric assessment (CGA) is defined as a multidisciplinary diagnostic and treatment process that identifies medical, psychosocial, and functional capabilities of an older adult in order to develop a coordinated plan to maximize overall health with aging. CGA is based on the premise that a systematic evaluation of frail older persons by a team of health professionals may identify a variety of treatable health problems and lead to better health outcomes.

    baseline

  • Biological parameters

    Characterization of the COVID-19 impact on the biological parameters evaluated by blood test.

    baseline

  • Medical imaging results

    Assessment of lesion extension (percent) with medical imaging results (thoracic scan)

    baseline

  • Diagnosis of COVID-19

    Recovery of the diagnosis method (PCR or thoracic scan)

    baseline

  • Length of hospitalization

    at the 3-month follow-up

  • Number of death from any cause

    at the 3-month follow-up

  • Reports of relevant investigations data provided by the physician and the family during the two-month telephone follow-up

    The demographic characteristics are age, sex, marital status, place of life, career, presence of un/formal assistance, …

    at the 3-month follow-up

  • Length of hospitalization

    at the 12-month follow-up

  • Number of death from any cause

    at the 12-month follow-up

  • Reports of relevant investigations data provided by the physician and the family during the two-month telephone follow-up

    The demographic characteristics are age, sex, marital status, place of life, career, presence of un/formal assistance, …

    at the 12-month follow-up

Eligibility Criteria

Age70 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

All consecutive patients meeting the eligibility criteria over the study period.

You may qualify if:

  • Hospitalization in the Geriatric unit of the University Hospital (UH) of Angers from 15/03/2020 and until the closure of the COVID-19 geriatric sector

You may not qualify if:

  • Opposition to the use of the information collected for research purposes.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Angers University Hospital

Angers, 49933, France

RECRUITING

Related Publications (1)

  • Briere O, Otekpo M, Asfar M, Gautier J, Sacco G, Annweiler C; GERIA-COVID study group. Initial functional disability as a 1-year prognostic factor in geriatric patients hospitalized with SARS-CoV-2 infection. PLoS One. 2023 Jul 27;18(7):e0289297. doi: 10.1371/journal.pone.0289297. eCollection 2023.

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Cédric ANNWEILER, MD, PhD

    University Hospital, Angers

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Cédric ANNWEILER, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
12 Months
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2020

First Posted

September 23, 2020

Study Start

March 15, 2020

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

December 20, 2021

Record last verified: 2021-12

Locations